Impactiviti Daily 042810 Top Pharma News

***** Note: there will be no Impactiviti Daily for the remainder of this week, as I’ll be away at a conference… TODAY’S NEWS Biotech: finally profitable – The biotechnology industry is finally profitable, according to a new report out today from Ernst & Young. The report states that biotech companies in the world’s largest hubs — [...]

Read Full Post »

Impactiviti Daily 042710 Top Pharma News

***** TODAY’S NEWS The name is changed, but the pump remains the same – Kapidex (proton pump inhibitor from Takeda) is now Dexilant. Covidien launches Exalgo (pain reliefe) and Pennsaid (NSAID anti-inflammatory). FDA panel to Acura: Nah – It was red faces all around at Acura Pharmaceuticals Thursday after an advisory committee voted almost unanimously [...]

Read Full Post »

Impactiviti Daily 042310 Top Pharma News

COMING UP SOON: BDI’s Social Communications and Healthcare half-day gathering. NYC, May 11 – all details here. I will be leading a roundtable. Use discount code IMPACT for $155 registration rate. ***** TODAY’S NEWS Allergan – Rolling high-stakes legal dice re: Botox. Here and here. Novo’s Victoza: nice results in comparison with Merck‘s Januvia. Plus, [...]

Read Full Post »

Impactiviti Daily 042210 Top Pharma News

***** TODAY’S NEWS Novartis gets niche transplant drug approved in US -  Drug developer Novartis AG said Thursday it received Food and Drug Administration for the organ-rejection drug Zortress. The drug was first approved outside the U.S. six years ago as Certican and is available in more than 70 countries. It is used to prevent [...]

Read Full Post »

Impactiviti Daily 042010 Top Pharma News

***** TODAY’S NEWS Busy days at Novartis: Licensing deal with Array for oncology drugs; major quarterly profit rise; buying up more generics with Oriel purchase; oral MS drug Gilenia draws closer to review; however, bad timing on Tekturna. Nexavar and tailored treatments for lung cancer – The study found that Nexavar prevented lung-cancer from progressing [...]

Read Full Post »

Impactiviti Daily 041910 Top Pharma News

***** TODAY: A Rant Instead of the usual digest of news items, today, a long-overdue rant, triggered by this blog post by Rich Meyer. The phrase I’m going to key in on: You can’t rotate people into an eMarketing role and expect them to develop cutting edge digital strategies because by the time they learn [...]

Read Full Post »

Impactiviti Daily 041510 – Today’s Top Pharma News

***** TODAY’S NEWS Novartis announces a major US reorganization, including re-aligned business units, and cuts. Ouch. Crystal ball – what will be the biggest drug(s) in 2014? Here are some educated guesses. Use Remicade early in Crohn’s, the results say – “The results are pretty definitive,” Sandborn told MedPage Today. “Most patients should receive infliximab [...]

Read Full Post »

Impactiviti Daily 041410

***** TODAY’S NEWS Merck, Schering, Merger, Management, Munificence – it pays to be an exec at an acquired pharmaco. What’s on the the docket for biotechs in the coming quarter? A nice, quick summary. Kids’ suicide risk appears to be level across all anti-depressants. Now:  what about the risk of untreated depression?? RECOMMENDED Software training [...]

Read Full Post »

Impactiviti Daily 041310

***** TODAY’S NEWS Hugely encouraging results for Novartis‘ new experimental (oral) MS treatment – Novartis’ Gilena has delivered an impressive performance in a Phase III trial in patients multiple sclerosis, cutting relapse rates by 62% in treatment-naïve patients and sustaining its effects for more than two years. Importantly, data from the two-year FREEDOMS study, presented [...]

Read Full Post »

Impactiviti Daily 041210

***** Coming up on May 11th: BDI’s Social Communications & Healthcare event – half day session in NYC with Case Studies and Roundtables (I’ll be leading one of the roundtables). Top speakers from J&J, Pfizer, and more! These are always great networking and learning events. Hope to see you there! For more information, including registration, [...]

Read Full Post »